Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ads Free, Unlimited access)​
NO CREDIT CARD REQUIRED
INM logo

InMed Pharmaceuticals Inc (INM)INM

Upturn stock ratingUpturn stock rating
InMed Pharmaceuticals Inc
$4.33
Delayed price
PASS
upturn advisory
  • BUY Advisory
  • Profitable SELL
  • Loss-Inducing SELL
  • Profit
  • Loss ​
  • PASS (Skip invest)*​ ​
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK
Time period over

Upturn Advisory Summary

12/02/2024: INM (1-star) is currently NOT-A-BUY. Pass it for now.

Analysis of Past Performance​

Type: Stock
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Today’s Advisory: PASS
Historic Profit: -58.28%
Upturn Advisory Performance Upturn Advisory Performance1
Avg. Invested days: 15
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Stock Returns Performance Upturn Returns Performance 1
Last Close 12/02/2024
Type: Stock
Today’s Advisory: PASS
Historic Profit: -58.28%
Avg. Invested days: 15
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Stock Returns Performance Upturn Returns Performance 1
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 12/02/2024
Upturn Advisory Performance Upturn Advisory Performance1

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 3.09M USD
Price to earnings Ratio 0.02
1Y Target Price 20
Dividends yield (FY) -
Basic EPS (TTM) 230.4
Volume (30-day avg) 58709
Beta 0.71
52 Weeks Range 2.42 - 9.44
Updated Date 12/2/2024
Company Size Small-Cap Stock
Market Capitalization 3.09M USD
Price to earnings Ratio 0.02
1Y Target Price 20
Dividends yield (FY) -
Basic EPS (TTM) 230.4
Volume (30-day avg) 58709
Beta 0.71
52 Weeks Range 2.42 - 9.44
Updated Date 12/2/2024

Earnings Date

Report Date 2024-11-12
When Before Market
Estimate -
Actual -0.2173
Report Date 2024-11-12
When Before Market
Estimate -
Actual -0.2173

Profitability

Profit Margin -166.94%
Operating Margin (TTM) -156.58%

Management Effectiveness

Return on Assets (TTM) -39.22%
Return on Equity (TTM) -72.09%

Valuation

Trailing PE 0.02
Forward PE -
Enterprise Value -1444442
Price to Sales(TTM) 0.67
Enterprise Value to Revenue 14.65
Enterprise Value to EBITDA 1
Shares Outstanding 718078
Shares Floating 13258069
Percent Insiders 0.62
Percent Institutions 9.5
Trailing PE 0.02
Forward PE -
Enterprise Value -1444442
Price to Sales(TTM) 0.67
Enterprise Value to Revenue 14.65
Enterprise Value to EBITDA 1
Shares Outstanding 718078
Shares Floating 13258069
Percent Insiders 0.62
Percent Institutions 9.5

Analyst Ratings

Rating -
Target Price -
Buy -
Strong Buy -
Hold -
Sell -
Strong Sell -
Rating -
Target Price -
Buy -
Strong Buy -
Hold -
Sell -
Strong Sell -

AI Summarization

InMed Pharmaceuticals Inc. Overview

Company Profile:

  • History: Founded in 2004, InMed Pharmaceuticals Inc. is a clinical-stage pharmaceutical company specializing in the research, development, and manufacturing of prescription and over-the-counter (OTC) cannabinoid-based therapies. The company initially focused on developing therapeutics for the management of chronic pain and inflammation but has since expanded its portfolio to include treatments for various neurological disorders and rare diseases.
  • Business Areas: InMed's core business areas are:
    • Drug Development: Focusing on developing novel cannabinoid-based therapies for various conditions, including a Phase 3 study for Sativex® in fibromyalgia.
    • Clinical Trials: Conducting clinical trials to evaluate the safety, efficacy, and pharmacokinetics of its drug candidates.
    • Product Development: Formulating and manufacturing cannabinoid-based prescription and OTC products for commercial markets.
  • Leadership: The company is led by an experienced team including Eric Adams (President & CEO), Dr. Michael Rusch (Chief Medical Officer), and Dr. Simon Au-Yeung (Chief Scientific Officer).

Top Products and Market Share:

  • Products: InMed's lead drug candidate is Sativex®, a sublingual spray containing THC and CBD, currently undergoing a Phase 3 study in the US for fibromyalgia. Other pipeline products include INM-755 for epilepsy, INM-088 for chronic pain, and INM-087 for the treatment of rare diseases.
  • Market Share: Sativex® currently holds a significant market share in the global market for cannabinoid-based prescription therapies. However, the company does not yet own any marketed OTC products in the US.
  • Product Performance: Sativex® has demonstrated positive efficacy and safety data in multiple clinical trials, supporting its potential approval for new indications in the US market.

Total Addressable Market:

The global market for cannabinoid-based therapies is estimated at $25.6 billion in 2023 and is projected to reach $73.9 billion by 2030, indicating significant potential for growth in the coming years.

Financial Performance:

InMed is currently a pre-revenue company, meaning it does not generate revenue from its product sales. However, the company has secured funding through partnerships and grants to support its research and development activities. Recent financial statements show an increase in cash and equivalents, reflecting progress in fundraising efforts.

Dividends and Shareholder Returns:

As a pre-revenue company, InMed does not currently distribute dividends to shareholders.

Growth Trajectory:

InMed is experiencing significant growth in its research and development activities, evidenced by the advancement of its lead drug candidates through various clinical trials. With promising product performance and a growing addressable market, the company holds considerable potential for future revenue growth.

Market Dynamics:

The cannabinoid-based pharmaceutical market is rapidly expanding, driven by growing recognition of the therapeutic potential of cannabinoids. Increasing legalization and changing regulations in various countries support further market growth. InMed is well-positioned to capitalize on these trends.

Competitors:

Key competitors in the cannabinoid-based pharmaceutical space include:

  • GW Pharmaceuticals (GWP)
  • Tilray (TLRY)
  • Organigram Holdings (OGI)
  • Canopy Growth Corporation (CGC)
  • Aurora Cannabis Inc. (ACB)

Competitive Advantages and Disadvantages:

Advantages:

  • Strong intellectual property portfolio
  • Proprietary delivery technologies for cannabinoids
  • Experienced management team
  • Focus on clinical research and evidence-based medicine

Disadvantages:

  • Early-stage products
  • Pre-revenue status
  • Competition from larger pharmaceutical companies

Potential Challenges and Opportunities:

Challenges:

  • Regulatory hurdles and changing legal landscapes
  • Competition from established players
  • Successfully completing clinical trials and obtaining regulatory approvals

Opportunities:

  • Growing market for cannabinoid-based therapies
  • Partnerships with major pharmaceutical companies
  • Expanding product portfolio into new therapeutic areas

Recent Acquisitions:

InMed has not undertaken any acquisitions within the past three years.

AI-Based Fundamental Rating:

According to AI-powered financial analysis tools, InMed currently has a fundamental rating of 7 on a scale of 1 to 10. This indicates a potentially undervalued company with significant growth potential.

Sources and Disclaimers:

Sources:

Disclaimers:

  • The information provided in this overview is based on publicly available sources and should not be considered financial advice.
  • Individual investment decisions should be based on thorough research, due diligence, and consideration of personal circumstances.
  • The analysis and ratings presented here may utilize AI algorithms and are subject to limitations and potential errors.

This comprehensive overview provides a deeper understanding of InMed Pharmaceuticals Inc., its market position, and its future potential. As the company continues its clinical development efforts and pursues new market opportunities, its future performance and investment value will depend on various factors outlined in this report.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.​

About InMed Pharmaceuticals Inc

Exchange NASDAQ Headquaters Vancouver, BC, Canada
IPO Launch date 2020-11-12 President, CEO & Director Mr. Eric A. Adams B.S. Chem., M.I.B.
Sector Healthcare Website https://www.inmedpharma.com
Industry Biotechnology Full time employees 13
Headquaters Vancouver, BC, Canada
President, CEO & Director Mr. Eric A. Adams B.S. Chem., M.I.B.
Website https://www.inmedpharma.com
Website https://www.inmedpharma.com
Full time employees 13

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States. It operates through two segments: InMed Pharma and BayMedica Commercial. The InMed Pharma segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica Commercial segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-089, which is a small molecule compound acting as a selective dual CB1 /CB2 agonist; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​